• search
  • site map
  • contact

XDX - Expression Diagnostics

XDX - Expression Diagnostics
  • Home
  • About XDX
  • Technology
  • Development Programs
  • News & Events
  • Investors
  • Careers
  • AlloMap
  • vcs
  • corporate governance

VCs

 

XDx is a venture-backed, privately held molecular diagnostics company. XDx’s investors are leaders in life science investing. They bring to XDx extensive strategic, financial, scientific and practical expertise.

 

Kleiner Perkins Caufield & Byers

Kleiner Perkins Caufield & Byers (KPCB) is an active venture capital partnership headquartered in the San Francisco Bay Area with a large capital base for investment. Since 1972, KPCB has invested in over 525 technology companies (including 85 in biotechnology and medical devices), which have accrued market valuations exceeding $450 billion and employ more than 295,000. In this process, KPCB has been privileged to work with some of America 's most outstanding entrepreneurs, chief executive officers and management teams.

TPG Ventures

Texas Pacific Group (TPG) is a private equity investment firm founded by David Bonderman, James G. Coulter and William S. Price, III in 1993. The principals of TPG, with affiliated partnerships, have aggregate committed capital of more than $5 billion. TPG's diverse holdings include Oxford Health Plans, Magellan Health Services, Paradyne Networks, Ducati Motor, J. Crew Group, Landis & Gyr Communications and WR Hambrecht + Co. Founded in 2001, Texas Pacific Group Ventures has a total of $500M devoted to investments in information technology and the life sciences in the United States.

The Sprout Group (whose healthcare investments are managed by New Leaf Venture Partners)

The Sprout Group is one of the oldest and largest institutional venture capital firms focused on emerging technology companies. Since its founding in 1969, Sprout Group has financed more than 350 companies and has raised nearly $3.0 billion in committed capital from leading institutional investors and individuals active in the technology industry. In November 2000, Sprout Group closed Sprout IX, a fund totaling $1.1 billion. Sprout Group's investment focus is in communications, software and healthcare technology, industries with rapid long-term growth and significant structural changes. Sprout Group seeks existing or potential market leaders within these sectors and will invest in companies at all stages from start-up through buyout. New Leaf Venture (NLV) Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded in 2005 by the former members of Sprout Group's Healthcare Technology venture team, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices and molecular diagnostics. In addition, the NLV Partners team continues to manage the existing $800 million healthcare technology portfolio of Sprout Group.

Burrill & Company
Burrill & Company is a San Francisco-based global leader in life sciences with principal activities in private equity/venture capital, merchant banking and media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. The company’s over 60 person scientific and business team, supported by its advisory boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life sciences companies and managements, provide Burrill with unparalleled access and insight.
Duff, Ackerman & Goodrich
Duff Ackerman & Goodrich (DAG) Ventures invests in technology leaders at the forefront of new, large markets. Based in San Francisco, CA we seek to invest in those entrepreneurial teams able to overcome the obstacles that lead big problems to become big markets. Our investments span entrepreneurial companies in the life science, materials, traditional IT and other sectors.
Intel Capital Partners
With an overall strategy to enable innovation, Intel Capital seeks out and invests in promising technology companies worldwide. We focus on both established and new technologies that help to develop industry standard solutions, drive global Internet growth, facilitate new usage models, and advance the computing and communications platforms.
Integral Capital Partners
Integral Capital Partners operates a family of partnerships that invests in expansion-stage private and growth-stage public companies in the information and life sciences industries. In the life sciences sector, Integral focuses on emerging medical technologies. Integral's investments include Genomic Health, Inc., NuVasive, Inc. Revenue Science, Inc. and Tropos Networks, Inc.

 

©2004-2008 XDx, Inc. All Rights Reserved.

  • Privacy & Compliance